Company profile: Spark Therapeutics
1.1 - Company Overview
Company description
- Provider of potentially curative, one-time gene therapy treatments for genetic diseases, including investigational programs such as SPK-8011 for hemophilia A, fidanacogene elaparvovec (SPK-9001) for hemophilia B, SPK-3006 for Pompe disease, and gene therapies targeting Stargardt and Huntingtonβs diseases, plus AAV-based research programs for the retina, liver, and central nervous system.
Products and services
- Fidanacogene elaparvovec (SPK-9001): A custom-engineered AAV vector for hemophilia B, delivering a high-activity F9 transgene to potentially correct factor IX deficiency in a one-time treatment
- Gene Therapy Research Programs: Platform-scale AAV research targeting the retina, liver, and central nervous system, creating candidates for various genetic diseases via tissue-specific vector design
- SPK-8011: An investigational-grade, potentially one-time gene therapy for hemophilia A, aiming to address blood coagulation deficiencies due to mutations in the F8 gene.
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Spark Therapeutics
Foghorn Therapeutics
HQ: United States
Website
- Description: Provider of targeted therapies leveraging its Gene Traffic Control platform to modulate the chromatin regulatory system, including FHD-286, an enzymatic BRG1/BRM inhibitor for AML and MDS; a selective BRM inhibitor and degrader for cancers with BRG1 mutations; and an ARID1B degrader for cancers with ARID1A mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Foghorn Therapeutics company profile β
Phio Pharmaceuticals
HQ: United States
Website
- Description: Provider of RNAi immuno-oncology therapies leveraging the INTASYL self-delivering RNAi platform to create siRNA compounds that silence gene targets. Pipeline includes PH-762 (intratumoral PD-1 silencing for cSCC, melanoma, Merkel cell carcinoma), PH-894 (intratumoral BRD4 silencing for advanced melanoma and other cancers), and PH-762 + adoptive cell therapy with double positive CD8 Tils (IV for stage IV melanoma and solid tumors).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Phio Pharmaceuticals company profile β
Elsie Biotechnologies
HQ: United States
Website
- Description: Provider of RNA therapeutics and oligonucleotide discovery technologies, including a proprietary ultra-high throughput platform that evaluates oligonucleotide chemical space to optimize therapeutic candidates for activity, toxicity, and delivery, and P(V) chemistry technologies with novel reagents and processes to synthesize diverse oligonucleotide therapeutics with complete synthetic control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Elsie Biotechnologies company profile β
Biogazelle
HQ: Belgium
Website
- Description: Provider of genomic testing solutions and expert laboratory services in nucleic acid quantificationβincluding gene expression, mutation, and copy number analysisβand antisense oligonucleotide screening to support development of diagnostics and therapeutics. Offers customized workflows for clinically relevant samples, from liquid biopsies to fixed tissues.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Biogazelle company profile β
Genenta
HQ: Italy
Website
- Description: Provider of gene transfer therapy for cancer, including Temferon, a lentiviral hematopoietic stem progenitor cell immunotherapy enabling controlled, targeted interferon-Ξ± expression within tumors to generate immune responses to TEMs-positive cancers. Offers a proprietary cell-based platform using hematopoietic stem cells to deliver therapeutic payloads in the tumor microenvironment for durable, safe treatment of solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Genenta company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Spark Therapeutics
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spark Therapeutics
2.2 - Growth funds investing in similar companies to Spark Therapeutics
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Spark Therapeutics
4.2 - Public trading comparable groups for Spark Therapeutics
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β